Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Iron Level and Myelin Content in the Ventral Striatum Predict Memory Performance in the Aging Brain.
Comment on the letter by Messori et al. (European Journal of Neurology 2013; 20: e131).
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.
Submembranous cytoskeletons stabilize nodes of Ranvier.
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.
Study shows promising efficacy for peginterferon beta-1a in multiple sclerosis
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.
Optic neuritis in a child with biotinidase deficiency: case report and literature review.
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Review of MR elastography applications and recent developments.
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Successful desensitization to natalizumab in a skin test--positive patient: a case report.
Optic nerve disease and axon pathophysiology.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
[Vitamin D for prevention of diseases?].
Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].
Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset.
Biplanar MRI for the assessment of the spinal cord in multiple sclerosis.
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.
Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Pages
« first
‹ previous
…
122
123
124
125
126
127
128
129
130
…
next ›
last »